Iterative Health, a company specializing in technology and services to accelerate clinical research, has appointed Nadege Gunn, MD, CPI, DABOM, FAASLD as Chief Medical Officer, Hepatology and Obesity, the company announced Saturday.
Dr. Gunn will provide medical and scientific leadership for research activities in hepatology and obesity, overseeing medical affairs, specialized clinical site development, and collaboration with biopharmaceutical sponsors and contract research organizations (CROs). The appointment is intended to support the rapid expansion of Iterative Health’s therapeutic portfolio and accelerate access to innovative therapies, according to the company.
The move aligns with Iterative Health’s strategy to build a network of high-performing clinical centers capable of expanding access to multispecialty trials and reducing the time to develop novel treatments.
Dr. Gunn is a gastroenterologist, hepatologist, and obesity medicine specialist with over 15 years of experience as a Principal Investigator in more than 100 Phase I and Phase II clinical trials. Her expertise covers the full spectrum of metabolic liver diseases, including MASH and MASLD, and she has a proven track record of translating complex protocols into effective research programs, even in community settings.
Currently, Dr. Gunn directs the hepatology clinic at Coryell Health. She is also the founder and former President and Chief Executive Officer of Impact Research Institute in Waco, Texas, a nationally recognized center for hepatology research. She has also held academic appointments at Texas A&M University, Dell Medical School at The University of Texas at Austin, and Baylor University, contributing to the training of future physicians, and researchers.
Dr. Gunn is also a key member of the Women in Hepatology: Initiatives, Sponsorship, and Empowerment (WHISE) committee of the Chronic Liver Disease Foundation (CLDF), which focuses on the advancement of women in the field.
In a separate announcement, Iterative Health promoted Dana Feuchtbaum from Chief Product Officer to Chief Operating Officer, with responsibility for operations and technology development across the company’s global network of clinical sites, which spans four continents.
The appointments are intended to build an integrated leadership team focused on supporting increasingly complex clinical trials in hepatology and metabolic disease.
